TGF-β treatment of lung cancer cells resulted in increased invasive and migratory potential, which was further enhanced by NM23-H1 knockdown, meaning that NM23-H1 emerges as a new upstream factor acting against epithelial-mesenchymal transition [79]. The gene discussed is NME1; the disease is lung cancer.